Тематические порталы ИД "Русский врач": Аллергология, Гастроэнтерология, Геронтология, Гинекология, Кардиология, Педиатрия, Неврология, Травматология, Эндокринология, Эпидемиология

Конкурсы и гранты

Стратегия применения хондропротекторов при остеоартрозе
Автор: С. Носков, А. Лаврухина, К. Широкова и др.   



Стратегия применения хондропротекторов при остеоартрозе

Рассматривается возможное влияние хондропротекторов на углеводный обмен, что особенно важно с учетом высокой коморбидности остеоартроза по сахарному диабету. Представлены современные клинические рекомендации по применению хондропротекторов в терапии остеоартроза.
A strategy for the use of chondroprotective agents in osteoarthrosis
The paper considers whether chondroprotective agents may have an effect on carbohydrate metabolism, which is particularly important in terms of the high comorbidity of osteoarthrosis with diabetes mellitus. It presents current clinical guidelines for the use of chondroprotective agents in the therapy of osteoarthrosis.


  1. Albert S., Oiknine R., Parseghian S. et al. The effect of glucosamine on Serum HDL cholesterol and apolipoprotein AI levels in people with diabetes // Diabetes Care. – 2007; 30 (11): 2800–3.
  2. Anderson J., Nicolosi R., Borzelleca J. Glucosamine effects in humans: A review of effects on glucose metabolism, side effects, safety considerations, and efficacy // Food Chem. Toxicol. – 2005; 43 (2): 187–201.
  3. Bauerova K., Ponist S., Kuncirova V. et al. Chondroitin sulfate effect on induced arthritis in rats // Osteoarthritis. Cartilage. – 2011; 19 (11): 1373–9.
  4. Biggee B., Blinn C., Nuite M. et al. Effects of oral glucosamine sulphate on serum glucose and insulin during an oral glucose tolerance test of subjects with osteoarthritis // Ann. Rheum. Dis. – 2007; 66 (2): 260–2.
  5. Daren A., Allison A., Mark D. The effect of glucosamine-chondroitin supplementation on glycosylated hemoglobin levels in patients with type 2 diabetes mellitus // Arch. Intern. Med. – 2003; 163: 1587–90.
  6. Dostrovsky N., Towheed T., Hudson R. et al. The effect of glucosamine on glucose metabolism in humans: a systematic review of the literature // Osteoarthritis. Cartilage. – 2011; 19 (4): 375–80.
  7. Hochberg M.C. Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials of 2-year duration // Osteoarthritis. Cartilage. – 2010; 18 (Suppl. 1): 28–31.
  8. Hochberg M., Altman R., April K. et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee // Arthritis Care. Res. (Hoboken). – 2012; 64 (4): 455–74.
  9. Jerosch J. Effects of Glucosamine and Chondroitin Sulfate on Cartilage Metabolism in OA: Outlook on Other Nutrient Partners Especially Omega-3 Fatty Acids // Int. J. Rheumatol. – 2011; 2011: 969012.
  10. Kahan A., Uebelhart D., De Vathaire F. et al. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial // Arthritis. Rheum. – 2009; 60: 524–33.
  11. Lee Y., Woo J., Choi S. et al. Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis // Rheumatol. Int. – 2010; 30 (3): 357–63.
  12. Muniyappa R., Karne R., Hall G. et al. Oral glucosamine for 6 weeks at standard doses does not cause or worsen insulin resistance or endothelial dysfunction in lean or obese subjects // Diabetes. – 2006; 55 (11): 3142–50.
  13. Palma Dos Reis R., Giacovelli G., Girolami F. et al. Crystalline glucosamine sulfate in the treatment of osteoarthritis: evidence oflongterm cardiovascular safety from clinical trials // Open Rheumatol. J. – 2011; 5: 69–77.
  14. Pecchi E., Priam S., Mladenovic Z. et al. A potential role of chondroitin sulfate on bone in osteoarthritis: inhibition of prostaglandin E₂ and matrix metalloproteinases synthesis in interleukin-1β-stimulated osteoblasts // Osteoarthrit. Cartilage. – 2012; 20 (2): 127–35.
  15. Pham T., Cornea A., Blick K.E. et al. Oral glucosamine in doses used to treat osteoarthritis worsens insulinresistance // Am. J. Med. Sci. – 2007; 333 (6): 333–9.
  16. Radimer K., Bindewald B., Hughes J. et al. Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999–2000 // Am. J. Epidemiol. – 2004; 160 (4): 339–49.
  17. Reichenbach S., Sterchi R., Scherer M. et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip // Ann. Intern. Med. – 2007; 146 (8): 580–90.
  18. Sawitzke A., Shi H., Finco M. et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT // Ann. Rheum. Dis. – 2010; 69 (8): 1459–64.
  19. Silbert J. Dietary glucosamine under question // Glycobiol. – 2009; 19 (6): 564–7.
  20. Simon R., Marks V., Leeds A. et al. A comprehensive review of oral glucosamine use and effects on glucose metabolism in normal and diabetic individuals // Diabetes Metab. Re.s Rev. – 2011; 27 (1): 14–27.
  21. Towheed T., Maxwell L., Anastassiades T. et al. Glucosamine therapy for treating osteoarthritis // Cochrane Database Syst. Rev. – 2005; 2: CD002946.
  22. Vista E., Lau C. What about supplements for osteoarthritis? A critical and evidenced-based review // Int. J.Rheumat. Dis. – 2011; 14: 152–8.
  23. Vlad S., LaValley M., McAlindon T. et al. Glucosamine for pain in osteoarthritis: why do trial results differ? //Arthr. Rheum. – 2007; 56: 2267–77.
  24. Volpi N. Anti-inflammatory activity of chondroitin sulphate: new functions from an old natural macromolecule // Inflammopharmacol. – 2011; 19 (6): 299–306.
  25. Wandel S., Juni P., Tendal B. еt al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis // BMJ. – 2010; 341: 4675.
  26. Wildi L., Raynauld J., Martel-Pelletier J. et al. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI // Ann. Rheum. Dis. – 2011; 70 (6): 982–9.




→ Фармакопейные статьи

→ Медицинские архивы на службе современного врача

→ Перечень медицинских технологий

ЭКД архив


Информационные партнеры: